|
The purpose is to exam prospective if simple clinical information in combination with a normal s-procalcitonin are sufficient for exclusion of infective endocarditis (IE).
U.S. FDA Resources
Further study details as provided by University of Aarhus:
Detailed Description: Despite progress in surgical and medical treatment, infective endocarditis is still associated with high morbidity and mortality. The variable clinical presentation of IE makes the diagnosis a clinical challenge. Procalcitonin is a precursor from the hormone calcitonin and also a marker of systemic bacterial infections. The purpose of this study is:
Eligibility
Criteria Inclusion Criteria:
Exclusion Criteria:
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00524212 Contacts
Locations
Sponsors and Collaborators
Investigators
More Information
Study placed in the following topic categories:
Additional relevant MeSH terms:
Source: National Library of Medicine (NLM) June 26, 2008 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Browse
|
||

